Serum Institute of India (SII) is doing its best to ramp up the production of COVID-19 vaccine Covishield to cater to demand in the country, Adar Poonawalla said on Saturday.
Responding to a tweet by JSW Group Chairman Sajjan Jindal, Poonawalla said the vaccine major is doing its best to introduce vaccines on priority for the Indian market.
“Yes @sajjanjindal, we at @SerumInstIndia are doing our best to ramp up production & launch new vaccines on priority for India. We are grateful for @TheJSWGroup efforts in trying to fulfill India’s medical oxygen needs as we stand together in this fight against this pandemic,” Poonawalla said in a tweet.
Yes @sajjanjindal, we at @SerumInstIndia are doing our best to ramp up production & launch new vaccines on priority for India. We are grateful for @TheJSWGroup efforts in trying to fulfill India’s medical oxygen needs as we stand together in this fight against this pandemic. https://t.co/B4AorR84Lx
— Adar Poonawalla (@adarpoonawalla) May 15, 2021
Earlier Sajjan Jindal had tweeted while tagging SII, Poonawalla , Bharat Biotech and its Managing Director Krishna Ella: “The only way we can win the #FightAgainstCOVID19 in India is to vaccinate everybody. Great to see @SerumInstIndia @adarpoonawalla and @BharatBiotech @krishnaella ramping up their capacities.”
Both SII and Bharat Biotech are in the forefront of supplying COVID-19 vaccines in the country even as the second wave of the pandemic continues to ravage various states.
